NEW YORK (GenomeWeb) – Ambry Genetics announced today that it has signed an agreement to integrate its AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.